Heart check: experimental drug ziresovir put to the test in healthy adults

NCT ID NCT06591845

Completed Knowledge-focused Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested whether the experimental drug ziresovir affects the heart's electrical activity in 34 healthy adults. Participants received different doses of ziresovir, a placebo, and an active control (moxifloxacin) to compare effects. The main goal was to measure changes in the QT interval, a key heart rhythm safety marker. Results will help determine if ziresovir is safe for future studies in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ziresovir
What this could lead to: If successful, this study could confirm that ziresovir is safe for the heart, supporting its use in treating respiratory infections.
What could go wrong: This is an early-phase safety study in healthy people, not patients. It only looks at heart effects and does not test if the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

California Clinical Trials Medical Group, Inc.

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.